logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
P

Philippe L. Bédard

university of toronto
H指数:68
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Primary Retroperitoneal Lymph Node Dissection in Marker-Positive Clinical Stage II Nonseminomatous Germ Cell Tumors (vol 215, pg 326, 2026)

标志物阳性临床II期非精原细胞瘤生殖细胞肿瘤的初次腹膜后淋巴结清扫术（vol 215, pg 326, 2026）

Journal of Urology
IF6.8
2026-07-010
PRE
Mousa, Ahmad; Chavarriaga, Julian; Kaushal, Sanchit; Burrafato, Zacharia; Anson-Cartwright, Lynn; Atenafu, Eshetu G.; Bedard, Philippe; Jiang, Di Maria; Glicksman, Rachel; Chung, Peter; Warde, Padraig; O'Malley, Martin; Prendeville, Susan; Jewett, Michael A. S.; Hamilton, Robert J.
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy

基于甲基化的循环肿瘤DNA在CDK4/6抑制剂治疗期间对转移性乳腺癌的监测

Nature Communications
IF15.7
2026-06-040
OAAI
Mitchell J. Elliott; Jesús Fuentes-Antrás; Sasha C. Main; Aaron Dou; Elizabeth Shah; Caroline Weipert; Geethika Yalamanchili; Taylor Bird; June Roh; Celeste Yu; Michelle B. Nadler; Eitan Amir; Hal K. Berman; Lillian L. Siu; Philippe L. Bedard; David W. Cescon
Postchemotherapy orchiectomy in metastatic testicular germ cell tumors: Pathologic findings and predictors of residual viable disease

术后化疗或睾丸切除术在转移性睾丸生殖细胞肿瘤中的病理发现和残余存活病灶的预测因子

Urologic Oncology-Seminars and Original Investigations
IF2.3
2026-06-010
PRE
Mousa, Ahmad; Hayes, James; Amiri, Ali; Anson-Cartwright, Lynn; Atenafu, Eshetu G.; Bedard, Philippe; Jiang, Di Maria; Glicksman, Rachel; Chung, Peter; Warde, Padraig; O'Malley, Martin; Prendeville, Susan; Hamilton, Robert J.
The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial

立体定向体部放射疗法在寡进展性乳腺癌中的作用：一项针对前瞻性、II期RADIANT试验的部位特异性分析

Clinical and Translational Radiation Oncology
IF2.7
2026-04-060
OAAI
Kara M. Ruicci; Joelle Helou; Aisling Barry; Xiang Y. Ye; C.Anne Koch; Jennifer Croke; Kathy Han; Danielle Rodin; Ezra Hahn; Jennifer Y.Y. Kwan; Michael Yan; Fei-Fei Liu; Patricia Lindsay; Joanna Javor; Philippe Bedard; David Cescon; Vikaash Kumar; Eitan Amir; Michelle B. Nadler; Ronita Lee
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors

Beamion PANTUMOR-1: Zongertinib二线临床试验的试验依据与设计，用于HER2过表达/扩增或HER2突变的实体瘤

Future Oncology
IF2.6
2026-03-040
PRE
Alison M. Schram; John J. Park; Antoine Italiano; Shigehisa Kitano; Ye Guo; Jin Li; Philippe L. Bedard; Cedric van Marcke; Ryo Ko; Lukas Lunger; Daniel M. Klotz; Jo Hussain; Daniela Maier; Damijan Erzen; David Planchard; Hans Prenen; Timothy D. Clay; Joon O. Park; Hyung-Don Kim; Alberto Hernando-Calvo; Yuta Maruki; Mariano Ponz-Sarvise; Ecaterina Dumbrava
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab

一种组织无关的全基因组甲基组富集检测的临床验证，用于监测帕博利珠单抗的治疗反应

npj Precision Oncology
IF8
2026-02-130
OAAI
Eric Y. Stutheit-Zhao; Yongqi Zhong; Collin A. Melton; Elizabeth D. Lightbody; Michael A. Hinterberg; Yarong Wang; Owen Hall; Eduardo V. Sosa; Jeremy B. Provance; Junjun Zhang; Abel Licon; Zhihui Amy Liu; Albiruni R. Abdul Razak; Anna Spreafico; Philippe L. Bedard; Aaron R. Hansen; Stephanie Lheureux; Pamela S. Ohashi; Alan Williams; Scott V. Bratman; Brian A. Allen; Jing Zhang; Daniel D. De Carvalho; Anne-Renee Hartman; Lillian L. Siu; Enrique Sanz-Garcia
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

Binimetinib和encorafenib用于非-V600E BRAF突变晚期实体瘤的治疗：来自BEAVER II期试验的结果

Nature Communications
IF15.7
2026-01-030
OAAI
April A. N. Rose; Jennifer Maxwell; Emmanuelle Rousselle; Chantel L. Mukonoweshuro; Islam E. Elkholi; Melody Riaud; Marco Biondini; Erica Cianfarano; Isabel Soria-Bretones; Chantal Tobin; Meghan McGuire; Rhoda W. Y. Law; Andrew J. Elia; Ben X. Wang; Ian King; Tong Zhang; Trevor J. Pugh; Zaid Saeed Kamil; Marcus Butler; Frances A. Shepherd; Natasha B. Leighl; Albiruni Abdul Razak; Aaron Hansen; Samuel D. Saibil; Philippe L. Bedard; Peter M. Siegel; Lillian L. Siu; David W. Cescon; Anna Spreafico
Evaluation of ensilication technology for ambient DNA preservation

常温DNA保存的硅化技术评估

NAR MOLECULAR MEDICINE
IF0
2026-01-010
PRE
Blas, Michael; Yu, Celeste; Aghababazadeh, Farnoosh Abbas; Hoelscher, Vanessa; Volz, Marcus; Morales, Linden; Jarolik, Kaytee; Dong, Xiuhua; Dobin, Sheila; Rantasalo, Tuula; Hirvonen, Tatu; Pursiheimo, Juha-Pekka; Laine, Nea; Homer, Nils; Chamoun, Cassandra; Pierce, William; Organick, Lee; Fehr, Adrian; Becich, Michael; Banal, James L.; Youens, Kenneth; Tamminen, Manu; Haibe-Kains, Benjamin; Bedard, Philippe
Author Correction: Advancing equitable access to innovation in breast cancer

作者更正：促进乳腺癌创新成果的公平获取

npj Breast Cancer
IF7.6
2025-12-160
OAAI
Seamus O’Reilly; Ines Vaz Luis; Virginie Adam; Evangelia D. Razis; Ander Urruticoechea; Amal Arahmani; Eva Carrasco; Boon H. Chua; Judith Bliss; Carolyn Straehle; Theodora Goulioti; Barbro Lindholm; Gustavo Werutsky; Etienne Brain; Philippe L. Bedard; Giuseppe Curigliano; Sherene Loi; Shigehira Saji; David Cameron
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
Cancer Research Communications
IF0
2025-11-010
OA
Parikh, Mamta; Uboha, Nataliya V.; Takebe, Naoko; Tam, Kit; Bedard, Philippe L.; Wisinski, Kari B.; Mittra, Arjun; Yin, Ming; Yang, Yuanquan; Noonan, Anne M.; Holleran, Julianne L.; Ruel, Christopher; Frankel, Paul; Beumer, Jan H.; Newman, Edward M.; Danilov, Alexey V.; Gore, Steven D.; Lara Jr, Primo N.
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab

细胞外DNA中的T细胞受体库作为接受帕博利珠单抗治疗患者肿瘤浸润细胞的替代标志物

Cell Reports
IF6.9
2025-08-270
PREAI
Shirin Soleimani; Xuan Li; Ben X. Wang; Stephanie Pedersen; Jeffrey P. Bruce; Jenna Eagles; Zhihui Amy Liu; Scott V. Bratman; Marcus O. Butler; Aaron R. Hansen; Philippe L. Bedard; Stephanie Lheureux; Anna Spreafico; Albiruni Razak; Lillian L. Siu; Pamela S. Ohashi; Trevor J. Pugh
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy

转移性HR+/HER2−乳腺癌患者在行内分泌和CDK4/6抑制剂治疗期间的个人化循环肿瘤DNA监测

npj Breast Cancer
IF7.6
2025-07-190
OAAI
Jesús Fuentes-Antrás; Mitchell J. Elliott; Sasha C. Main; Philippe Echelard; Aaron Dou; Philippe L. Bedard; Eitan Amir; Michelle B. Nadler; Nicholas Meti; Nancy Gregorio; Elizabeth Shah; Emily Van de Laar; Celeste Yu; Yangqing Deng; Lisa Gates; Clodagh Murray; Christopher G. Smith; Amber Chevalier; Scott V. Bratman; Lillian L. Siu; Hal K. Berman; David W. Cescon
Advancing equitable access to innovation in breast cancer

促进乳腺癌创新的公平获取

npj Breast Cancer
IF7.6
2025-07-100
OAAI
Seamus O’Reilly; Ines Vaz Luis; Virginie Adam; Evangelia D. Razis; Ander Urruticoechea; Amal Arahmani; Eva Carrasco; Boon H. Chua; Judith Bliss; Carolyn Straehle; Theodora Goulioti; Barbro Lindholm; Gustavo Werustsky; Etienne Brain; Philippe L. Bedard; Giuseppe Curigliano; Sherene Loi; Shigehira Saji; David Cameron
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

安全性概述及inavolisib单药和联合疗法在PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌中的管理（GO39374）

ESMO Open
IF8.3
2025-07-010
PRE
V. Gambardella; M.K. Accordino; P.L. Bedard; A. Cervantes; E. Hamilton; A. Italiano; K. Kalinsky; I.E. Krop; M. Oliveira; C. Saura; P. Schmid; N.C. Turner; A. Varga; A. Fernandez-Saranillo; Y. Jin; S. Royer-Joo; U. Peters; N. Shankar; J.L. Schutzman; D. Juric; K.L. Jhaveri
First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

FAZ053的首次人体研究，FAZ053是一种抗程序性死亡配体1（anti-PD-L1）单克隆抗体，单独使用及与spartalizumab（抗PD-1）联用，用于治疗晚期恶性肿瘤患者

ESMO Open
IF8.3
2025-06-010
PRE
F. Janku; D.S.P. Tan; J. Martin-Liberal; S. Takahashi; R. Geva; A. Gucalp; A. Razak; R. Kan; R. Reiners; J. Mataraza; S. Szpakowski; K. Subramanian; X. Chen; C. Lai; P.L. Bedard

研究方向

暂未获取到该数据
L
Lillian L. Siu
H 指数:101论文数:1,283被引数:4.0万
A
Aaron R. Hansen
H 指数:58论文数:690被引数:2.0万
A
Anna Spreafico
H 指数:45论文数:702被引数:9,266
D
David W. Cescon
H 指数:53论文数:405被引数:1.4万
T
Trevor J. Pugh
H 指数:79论文数:1,292被引数:4.3万
P
Padraig Warde
H 指数:78论文数:634被引数:2.5万
A
Albiruni R. Abdul Razak
H 指数:39论文数:223被引数:6,225
E
Eitan Amir
H 指数:74论文数:675被引数:2.3万
P
Peter Chung
H 指数:60论文数:619被引数:1.6万
R
Robert J. Hamilton
H 指数:52论文数:553被引数:1.0万